Login to Your Account

Mallinckrodt to acquire Infacare for its severe jaundice drug

By Michael Fitzhugh
Staff Writer

Friday, August 4, 2017

Mallinckrodt plc said it plans to acquire Infacare Pharmaceutical Corp., the developer of a late-stage severe jaundice treatment, for $80 million up front plus up to $345 million in potential milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription